Results 91 to 100 of about 2,538,615 (320)

Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer. [PDF]

, 2011
Patients reported a negative impact on the QoL of delayed emesis after chemotherapy. Poor prophylaxis of patients' nausea and vomiting after chemotherapy interferes with patients' QoL.
Atthobari, Jarir, Dwiprahasto, Iwan, Gelderblom, Hans, Guchelaar, Henk-Jan, Hakimi, Mohammad, Kaptein, Ad A, Mustofa, Mustofa, Nortier, Johan W R, Perwitasari, Dyah Aryani, Putter, Hein   +9 more
core   +1 more source

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

Journal of Clinical Oncology, 2019
PURPOSE In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non ...
M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman B. Rao, K. Hotta, K. Vandormael, A. Riccio, Jing Yang, M. Pietanza, J. Brahmer   +17 more
semanticscholar   +1 more source

Lonidamine Causes Inhibition of Angiogenesis-Related Endothelial Cell Functions

Neoplasia: An International Journal for Oncology Research, 2004
The aim of this study was to assess whether lonidamine (LND) interferes with some steps in angiogenesis progression. We report here, for the first time, that LND inhibited angiogenic-related endothelial cell functions in a dose-dependent manner (1-50 μg ...
Donatella Del Bufalo, Daniela Trisciuoglio, Marco Scarsella, Giulia D'Amati, Antonio Candiloro, Angela Iervolino, Carlo Leonetti, Gabriella Zupi   +7 more
doaj   +1 more source

Nonlinear cancer chemotherapy: modelling the Norton-Simon hypothesis [PDF]

, 2018
A fundamental model of tumor growth in the presence of cytotoxic chemotherapeutic agents is formulated. The model allows to study the role of the Norton-Simon hypothesis in the context of dose-dense chemotherapy. Dose-dense protocols aim at reducing the period between courses of chemotherapy from three weeks to two weeks, in order to avoid tumor ...
arxiv   +1 more source

Chemotherapy planning and multi-appointment scheduling: formulations, heuristics and bounds [PDF]

arXiv, 2023
The number of new cancer cases is expected to increase by about 50% in the next 20 years, and the need for chemotherapy treatments will increase accordingly. Chemotherapy treatments are usually performed in outpatient cancer centers where patients affected by different types of tumors are treated.
arxiv  

Isoniazid plus Thioacetazone * compared with Two Regimens of Isoniazid plus PAS in the Domiciliary Treatment of Pulmonary Tuberculosis in South Indian Patients [PDF]

, 1966
Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have established that ambulatory treatment of pulmonary tuberculosis with a standard daily regimen of isoniazid plus PAS for one year yields satisfactory results. However, this regimen
Tuberculosis Chemotherapy Centre, Madras
core  

Cisplatin-based chemotherapy of testicular cancer - Two decades after a major breakthrough [PDF]

, 2000
Two decades ago the introduction of cisplatin-based combination chemotherapy has dramatically improved the prognosis of patients with metastatic testicular cancer, At present 3 cycles of cisplatin, etoposide and bleomycin are considered as standard ...
Gerl, Arthur
core   +1 more source

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

New England Journal of Medicine, 2009
BACKGROUND We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and ...
E. Van Cutsem, C. Köhne, E. Hitre, J. Zaluski, Chung-Rong Chang Chien, A. Makhson, G. D'Haens, T. Pintér, R. Lim, G. Bodoky, J. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen, P. Rougier   +17 more
semanticscholar   +1 more source

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. [PDF]

, 2019
BackgroundNovel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor ...
Bajorin, DF, Bellmunt, J, Choueiri, TK, Climent, MA, Culine, S, de Wit, R, Fong, L, Fradet, Y, Frenkl, TL, Gerritsen, W, Gurney, H, Lee, JL, Nam, K, Necchi, A, Perini, RF, Petrylak, DP, Quinn, DI, Sternberg, CN, Vaughn, DJ, Vogelzang, NJ   +19 more
core   +1 more source

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

New England Journal of Medicine, 2014
BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.
B. Solomon, T. Mok, Dong-Wan Kim, Yi-long Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, S. Iyer, A. Reisman, K. Wilner, J. Tursi, F. Blackhall   +14 more
semanticscholar   +1 more source